Arrhythmias & electrophysiologyDiagnostic or prognostic study
Symptoms Burden as a Clinical Outcomes Assessment in Heart Failure Patients With Atrial Fibrillation
- Methodological validation study (secondary analysis of the GENETIC-AF randomised trial)
Authors' conclusion
Measurement of symptoms burden throughout clinical trial follow-up is feasible in AF/HF
Study context
- Population
- Patients with heart failure (HF) and atrial fibrillation (AF) in a trial comparing 2 AF prevention treatments
- Participants
- 267 patients
- Comparison
- SxBAF vs time to first symptomatic AF event as a trial endpoint
Performance
As reported in the abstract
Validation of SxBAF (AFSQ linked to ECG-documented AF)
Correlation of SxBAF with device-detected AF burden (Spearman's ρ)
0.74; P < 0.0001
Further findings
SxBAF discrimination
- Identified treatment group differences in CV serious adverse events and AF interventions, and in recent-onset AF provided specificity for AF- or worsening HF-associated symptoms
- P < 0.001 for each
Original publication
Symptoms Burden as a Clinical Outcomes Assessment in Heart Failure Patients With Atrial Fibrillation. JACC Heart Fail. Published 20 November 2024. doi:10.1016/j.jchf.2024.08.023
Summarised from the published abstract; every number is checked against it